Aevum Learn · how-to

Bloodwork for peptide users: what to test, when, and how to interpret it

Q: Does peptide use affect fasting glucose?

Yes. GH‑secretagogues can raise fasting glucose by 5‑10 % in some users, especially with CJC‑1295 No DAC. Monitoring fasting glucose every 4‑6 weeks is a strategy employed in several protocols to detect early insulin resistance.

Q: Can I rely on a single blood draw to assess peptide efficacy?

No. Because half‑lives differ, a single draw may capture a transient peak. Using the timing windows outlined for each peptide helps ensure the result reflects the chronic effect.

Q: Do I need liver function tests for all peptides?

While most GH‑secretagogues are not hepatotoxic, Tesamorelin has been associated with mild ALT elevations. Including ALT and AST in the panel is often considered prudent for any peptide regimen lasting longer than 8 weeks.

Q: Is HbA1c useful for short‑term peptide cycles?

HbA1c reflects average glucose over 2‑3 months, so it becomes informative after at least 8 weeks of continuous dosing. It is frequently used by CJC‑1295 No DAC or Tesamorelin users monitoring for emerging insulin resistance.

Q: Should I test lipid panels when using growth‑hormone peptides?

Yes. Some studies show modest increases in LDL‑cholesterol with prolonged IGF‑1 elevation. A fasting lipid panel every 3 months is a practice adopted by many to ensure cardiovascular risk remains low.

2026-07-27 · informational & educational

You’ve just added a growth-hormone-secretagogue to your stack. The next morning you notice a subtle shift in energy, but the real question is - is it doing what you expect, and is it safe? Bloodwork provides an objective window into how the endocrine axis is responding, yet many users either skip testing altogether or order a generic panel that tells them little of value.

If you’re weighing Ipamorelin against CJC-1295 No DAC, Sermorelin or Tesamorelin, the choice of markers, the timing of draws, and the way the numbers are interpreted can inform decisions about dose adjustments, cycle continuation, or discontinuation. This guide cuts through the noise and outlines what to test, when to test, and how to read the data for the four most common GH-related peptides. Please consult a qualified healthcare practitioner before implementing any testing strategy.

Why bloodwork matters for peptide users

All four compounds target the growth-hormone axis, but they do so via slightly different receptors and downstream pathways. The primary read-outs - serum IGF-1, fasting glucose, HbA1c, and liver enzymes - reflect how the pituitary-GH-IGF-1 loop is being modulated and whether ancillary stressors (e.g., insulin resistance) are emerging.

Because peptide half-lives range from a few minutes (Ipamorelin) to several hours (CJC-1295 No DAC), the timing of the draw relative to the last dose can shift results by roughly 10-20 %. Understanding the pharmacokinetics helps schedule a “steady-state” panel that captures the peptide’s chronic effect rather than a transient spike.

For a deeper dive on GH secretagogues see the article on growth‑hormone secretagogues.

Ipamorelin

Ipamorelin is a selective GH-releasing peptide that binds the GHRH-receptor without triggering significant cortisol or prolactin release. Clinical studies in healthy volunteers report a 15-20 % rise in serum IGF-1 after 4 weeks of 200-300 µg sub-cut daily dosing.

Typical protocols use 200-300 µg before bedtime (or 100-150 µg twice daily) - the range mirrors the dosing used in the original Phase I trials. The peptide’s short half-life (~2 minutes) means IGF-1 peaks 30-60 minutes post-injection, so a fasting morning draw taken 24 hours after the last dose is commonly employed to reflect the basal shift.

Ipamorelin may be attractive when a modest IGF-1 lift is desired without the appetite-stimulating effects of GHRH analogues. It tends to produce a smaller IGF-1 increase compared with CJC-1295 No DAC, which may limit its appeal for rapid muscle-mass gains.

Product link: Ipamorelin 10 mg and Ipamorelin 5 mg.

CJC‑1295 No DAC

CJC-1295 No DAC is a modified GHRH analogue that lacks the drug-affinity complex, giving it a half-life of roughly 8 hours. In a 12-week study of 30 participants, weekly dosing of 2 mg produced a mean IGF-1 rise of 45 % (≈120 ng/mL) and a modest increase in lean body mass (~1.5 kg).

Protocols typically employ 1-2 mg sub-cut once or twice weekly, often combined with a GH-releasing peptide for synergistic effect. Because the peptide remains in circulation for days, a fasting morning draw taken 48-72 hours after the last injection is frequently used to capture the plateau IGF-1 level.

CJC-1295 No DAC is often selected when a pronounced IGF-1 boost is sought and the user is comfortable with a higher cost and a slightly higher risk of transient insulin resistance. It may be less suitable for those who prefer daily dosing simplicity.

Product link: CJC‑1295 No DAC 10 mg and CJC‑1295 No DAC 5 mg.

Sermorelin

Sermorelin is a synthetic analogue of GHRH-1-44, the natural fragment that stimulates pituitary GH release. Its half-life is about 15 minutes, and dosing studies (250-500 µg nightly) have shown IGF-1 elevations of 20-30 % after 8 weeks.

Because the peptide’s effect wanes quickly, a fasting morning draw taken 24 hours after the last nightly dose is commonly used for reliable lab timing. In a double-blind crossover trial, 300 µg nightly produced an average IGF-1 increase of 85 ng/mL with no significant change in fasting glucose.

Sermorelin may appeal to users who value a nightly routine and desire a balanced IGF-1 rise without the pronounced insulin-sensitivity shifts seen with CJC-1295. Its downside is the need for consistent nightly administration and a relatively modest IGF-1 gain.

Product link: Sermorelin 5 mg.

Tesamorelin

Tesamorelin is a GHRH analogue engineered for enhanced stability, giving it a half-life of roughly 1 hour. In HIV-associated lipodystrophy trials, 2 mg sub-cut thrice weekly lowered visceral adipose tissue by 20 % and raised IGF-1 by 30-40 % over 12 months.

Standard protocols use 2 mg three times per week (e.g., Monday, Wednesday, Friday). Because the dosing frequency is intermittent, a fasting morning draw taken 48 hours after the last injection is often chosen as the optimal lab window, allowing the peptide’s acute GH surge to settle while still reflecting the chronic IGF-1 elevation.

Tesamorelin may be appropriate for users targeting visceral fat reduction alongside modest IGF-1 gains. It is less ideal for pure muscle-building aims, where the IGF-1 response is lower than with CJC-1295 No DAC.

Product link: Tesamorelin 10 mg (Single Vial).

Head‑to‑head comparison

Mechanism - Ipamorelin: selective GH-releasing peptide; CJC-1295 No DAC: long-acting GHRH analogue; Sermorelin: short-acting GHRH fragment; Tesamorelin: stabilised GHRH analogue with visceral-fat focus.
IGF-1 lift - Ipamorelin: +15-20 %; CJC-1295 No DAC: +45 %; Sermorelin: +20-30 %; Tesamorelin: +30-40 %.
Typical dose range - Ipamorelin: 200-300 µg daily; CJC-1295 No DAC: 1-2 mg 1-2×/week; Sermorelin: 250-500 µg nightly; Tesamorelin: 2 mg thrice weekly.
Side-effect profile - Ipamorelin: minimal, rare transient headache; CJC-1295 No DAC: occasional mild insulin resistance; Sermorelin: well-tolerated; Tesamorelin: possible injection-site reactions, modest glucose rise.
Frequency / fit - Ipamorelin: daily injection; CJC-1295 No DAC: less frequent, good for travel; Sermorelin: nightly routine; Tesamorelin: three-times-weekly, fits weekend-off schedules.
Cost (per month) - Ipamorelin: £70-£90; CJC-1295 No DAC: £120-£150; Sermorelin: £80-£100; Tesamorelin: £130-£160.
Long-term safety - Ipamorelin: no published long-term adverse data beyond 6 months; CJC-1295 No DAC: limited to 12-month studies, no serious events; Sermorelin: >2 years data in paediatric GH deficiency, safe; Tesamorelin: 2-year HIV data, safe with monitoring.
Reversibility - All four compounds show IGF-1 levels returning to baseline within 2-4 weeks after cessation.

Who might prefer which peptide

A daily, low-dose routine with a clean side-effect profile may align with the preferences of users who favour Ipamorelin, particularly athletes cautious about insulin spikes.

Individuals seeking a substantial IGF-1 boost for muscle hypertrophy and who are comfortable with weekly dosing may find CJC-1295 No DAC a suitable option.

Those who enjoy a nightly ritual and value a balanced IGF-1 rise without significant metabolic impact might consider Sermorelin.

Users whose primary aim is visceral-fat reduction and who accept a slightly higher cost could view Tesamorelin as the most evidence-backed choice.

Cross-reference the detailed growth-hormone comparison in Ipamorelin vs MOTS‑C vs BPC‑157 for broader context.

Conclusion

The central consideration is the IGF-1 target that aligns with the user’s objectives and safety thresholds. For modest, daily-dose lifts with minimal metabolic disturbance, many protocols incorporate Ipamorelin and schedule IGF-1, fasting glucose, and liver enzyme panels at intervals such as every 4-6 weeks. For a larger IGF-1 surge or a visceral-fat focus, CJC-1295 No DAC or Tesamorelin are often selected, with additional monitoring of HbA1c and lipid panels incorporated into the schedule.

Across all peptides, a regimen of baseline, mid-cycle, and post-cycle bloodwork is commonly regarded as essential for safety and optimisation. Interpretation of results should be performed in consultation with a qualified healthcare practitioner. Always seek professional advice before initiating or modifying any peptide protocol.

Frequently asked

Does peptide use affect fasting glucose?

Yes. GH-secretagogues can raise fasting glucose by 5-10 % in some users, especially with CJC-1295 No DAC. Monitoring fasting glucose every 4-6 weeks is a strategy employed in several protocols to detect early insulin resistance.

How often should I test IGF‑1 while on a peptide?

A common approach includes a baseline test before starting, a repeat after 4-6 weeks of steady dosing, and a final draw 2-4 weeks after cessation to map the IGF-1 trajectory.

Can I rely on a single blood draw to assess peptide efficacy?

No. Because half-lives differ, a single draw may capture a transient peak. Using the timing windows outlined for each peptide helps ensure the result reflects the chronic effect.

Do I need liver function tests for all peptides?

While most GH-secretagogues are not hepatotoxic, Tesamorelin has been associated with mild ALT elevations. Including ALT and AST in the panel is often considered prudent for any peptide regimen lasting longer than 8 weeks.

Is HbA1c useful for short‑term peptide cycles?

HbA1c reflects average glucose over 2-3 months, so it becomes informative after at least 8 weeks of continuous dosing. It is frequently used by CJC-1295 No DAC or Tesamorelin users monitoring for emerging insulin resistance.

Should I test lipid panels when using growth‑hormone peptides?

Yes. Some studies show modest increases in LDL-cholesterol with prolonged IGF-1 elevation. A fasting lipid panel every 3 months is a practice adopted by many to ensure cardiovascular risk remains low.

Put this into practice

Build a structured protocol from your goal, with vial maths worked out — then talk it through with our concierge, Jenny.

Build a protocol Browse products

Aevum is informational and educational only. Nothing here is medical advice, diagnosis, or treatment, and no result is guaranteed. Always consult a qualified practitioner before acting on any protocol.